Skip to main content
Innate Pharma logo

Innate Pharma — Investor Relations & Filings

Ticker · IPH ISIN · FR0010331421 LEI · 9695002Y8420ZB8HJE29 PA Manufacturing
Open in API
Filings indexed 1,409 across all filing types
Latest filing 2021-05-28 Declaration of Voting R…
Country FR France
Listing PA IPH

About Innate Pharma

http://www.innate-pharma.com/

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Recent filings

Filing Released Lang Actions
Résultats de l’Assemblée Générale d'Innate Pharma
Declaration of Voting Results & Voting Rights Announcements Classification · 98% confidence The document is titled "RÉSULTATS DE L'ASSEMBLÉE GÉNÉRALE D'INNATE PHARMA" (Results of the General Meeting of Innate Pharma) and explicitly states the results of the shareholder vote held on May 28, 2021. It details the quorum, the re-election of board members, and directs readers to where the full resolutions and voting results are available. This content directly corresponds to the announcement of voting results from a general meeting. Therefore, the appropriate classification is Declaration of Voting Results & Voting Rights Announcements (DVA).
2021-05-28 French
Outcome of Innate Pharma’s Annual General Meeting
AGM Information Classification · 99% confidence The document is explicitly titled "OUTCOME OF INNATE PHARMA'S ANNUAL GENERAL MEETING" and details the voting results of the AGM held on May 28, 2021. This directly corresponds to the definition of AGM-R (AGM Information), which covers presentations and materials shared during the Annual General Meeting. Although it mentions voting results (which could relate to DVA), the primary focus and title indicate it is the summary/outcome of the AGM event itself. It is not a full 10-K, an ER, or an RPA, as it contains the substantive results, not just an announcement of a future report.
2021-05-28 English
FORM 6-K
Foreign Filer Report
2021-05-25 English
Nouveau Nombre D'Actions et de Droits de Vote d'Innate Pharma au 1er Mai 2021
Share Issue/Capital Change Classification · 95% confidence The document is a press release titled "NOUVEAU NOMBRE D'ACTIONS ET DE DROITS DE VOTE D'INNATE PHARMA AU 1ER MAI 2021" (New number of shares and voting rights of Innate Pharma as of May 1, 2021). It explicitly states that it is published in accordance with French Commercial Code articles and AMF (Autorité des marchés financiers) regulations, detailing the total number of shares and voting rights as of a specific date. This type of mandatory disclosure regarding the capital structure and voting rights is a specific type of regulatory filing related to share capital changes. While it relates to shares, it is not a general share issue announcement (SHA) but a mandatory periodic update on the total count. This fits best under the category of a general regulatory announcement or a specific filing related to capital structure updates. Given the options, the most precise fit for a mandatory disclosure of total shares and voting rights, often required when thresholds are crossed or periodically, is related to share capital changes or major shareholding notifications. Since it is a formal disclosure of the total share count used for calculating voting rights, it is closely related to 'Major Shareholding Notification' (MRQ) or a general 'Regulatory Filing' (RNS). However, since it is a formal announcement of the total number of shares and voting rights, which is a key component of capital structure reporting, and often required when thresholds are crossed, 'Major Shareholding Notification' (MRQ) is a strong candidate, although 'Regulatory Filings' (RNS) is the fallback. Given the content is a direct calculation of total shares and voting rights based on regulatory requirements (L. 233-8 II du Code de Commerce and 223-16 du règlement général de l'AMF), it is a specific regulatory disclosure. In many contexts, these periodic updates are grouped with major shareholding changes or general regulatory updates. Since the document explicitly details the total number of shares and voting rights, which is the basis for calculating major shareholdings, MRQ is plausible, but RNS is the safest general regulatory category if MRQ is strictly for *changes* crossing thresholds. Since this is a periodic update of the total count, and not explicitly a threshold crossing announcement, I will classify it as a general Regulatory Filing (RNS) as it is a mandatory disclosure to the AMF that doesn't fit the other specific categories perfectly, although it is related to capital structure.
2021-05-25 French
Number of Shares and Voting Rights of Innate Pharma as of May 1, 2021
Regulatory Filings Classification · 95% confidence The document is titled "NUMBER OF SHARES AND VOTING RIGHTS OF INNATE PHARMA AS OF MAY 1, 2021" and explicitly states it is released pursuant to the French "Code de Commerce" and AMF General Regulation to report the total number of shares outstanding and voting rights as of a specific date (May 1, 2021). This type of mandatory periodic disclosure regarding share capital structure and voting rights, often required by local market authorities (like the AMF in France), does not fit neatly into the primary financial report categories (10-K, IR, ER). It is a specific regulatory disclosure concerning ownership structure. Since it is a formal, required announcement that doesn't match the other specific categories (like Director's Dealing, Dividend Notice, or Capital Change), it best fits the general 'Regulatory Filings' fallback category (RNS), which covers miscellaneous regulatory announcements.
2021-05-25 English
FORM 6-K
Foreign Filer Report
2021-05-12 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.